<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM13129</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-13129</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Внедрение новых технологий инсулинотерапии и контроля гликемии в клинической практике в период 2016–2023 гг., и их влияние на достижение целевых показателей лечения у детей с сахарным диабетом 1 типа</article-title><trans-title-group xml:lang="en"><trans-title>The introduction of new technologies for insulin therapy and glycemic control in clinical practice in the period 2016-2023, and their impact on achieving treatment targets in children with type 1 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4316-8546</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лаптев</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Laptev</surname><given-names>D. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаптев Дмитрий Никитич - д.м.н.; Researcher ID: O-1826-2013; Scopus Author ID: 24341083800.</p><p>Москва</p></bio><bio xml:lang="en"><p>Dmitry N. Laptev - MD, PhD.; Researcher ID: O-1826-2013; Scopus Author ID: 24341083800.</p><p>Moscow</p></bio><email xlink:type="simple">laptevdn@ya.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0630-936X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Князева</surname><given-names>Т. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Knyazeva</surname><given-names>T. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Князева Тила Тимуровна - н.с.</p><p>Москва</p></bio><bio xml:lang="en"><p>Tila T. Knyazeva - MD, researcher.</p><p>Moscow</p></bio><email xlink:type="simple">shmushkovich_til@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9621-5732</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Безлепкина</surname><given-names>О. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Bezlepkina</surname><given-names>O. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Безлепкина Ольга Борисовна - д.м.н., проф.</p><p>Москва</p></bio><bio xml:lang="en"><p>Olga B. Bezlepkina - MD, PhD, Professor.</p><p>Moscow</p></bio><email xlink:type="simple">olgabezlepkina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГНЦ РФ ФГБУ «Национальный медицинский исследовательский центр эндокринологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2024</year></pub-date><volume>27</volume><issue>5</issue><fpage>461</fpage><lpage>467</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лаптев Д.Н., Князева Т.Т., Безлепкина О.Б., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Лаптев Д.Н., Князева Т.Т., Безлепкина О.Б.</copyright-holder><copyright-holder xml:lang="en">Laptev D.N., Knyazeva T.T., Bezlepkina O.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/13129">https://www.dia-endojournals.ru/jour/article/view/13129</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. Внедрение в клиническую практику современных технологий: помповая инсулинотерапия (НПИИ) и непрерывный мониторинг глюкозы (НМГ) значительно облегчил жизнь людей с сахарным диабетом 1 типа (СД1). Однако сопровождается ли это достижением лучшей компенсации у детей и подростков — этот вопрос пока не получил утвердительного ответа.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Проанализировать взаимосвязь гликемического контроля с использованием НПИИ и НМГ у детей.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. В исследование включены 6382 ребенка с СД1 в возрасте от 1 года до 18 лет, наблюдавшиеся в течение 8 лет (2016–2023 гг). Оценивали частоту использования НПИИ и НМГ и исследовали уровень гликированного гемоглобина (HbA1c) и % детей, имеющих HbA1с&lt;7,0%.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Уровень HbA1c снижался с 8,6% в 2016 г. до 7,7% в 2023 г. (р&lt;0,001). Параллельно увеличивался % детей, достигших HbA1c&lt;7,0% c 11 до 29%. За этот период использование НМГ выросло с 11,6 до 84%, НПИИ — с 38,7 до 42,3% (р&lt;0,001).</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Внедрение в клиническую практику НПИИ и НМГ значимо сопровождается улучшением компенсации СД1 у детей как по уровню HbA1c, так и увеличению процента детей, достигающих целевых значений HbA1c&lt;7,0%.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) improve daily life for people with Type 1 Diabetes Mellitus dramatically (T1D). However, there are still no compelling evidences that the use of insulin pumps (IP) and continuous glucose monitors (CGM) really help to improve diabetes control in children and adolescents.</p></sec><sec><title>AIM</title><p>AIM: to analyze the relation between diabetes control and the use of insulin pumps and continuous glucose monitors in children.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: 6382 children with T1D aged 1–18 years were enrolled in this study. Frequency of CSII and CGM use, HbA1с level and the percentage of children with HbA1с&lt; 7.0% were analyzed.</p></sec><sec><title>RESULTS</title><p>RESULTS: HbA1c decreased from 8.6% to 7.7% for 7 years (p&lt;0.001). Simultaneously the quantity of children with HbA1c&lt;7.0% increased from 11% to 29%. During this period the use of CGM increases dramatically from 11.6% to 84%. The use of IP increases from 38.7% to 42.3% (p&lt;0.001).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: CSII and continuous glucose monitors use statistically significant improves T1D control in children according to mean HbA1c level decrease and the quantity of children with target HbA1c level increase.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>непрерывная подкожная инфузия инсулина (помповая инсулинотерапия)</kwd><kwd>непрерывный мониторинг глюкозы</kwd><kwd>сахарный диабет у детей</kwd><kwd>гликированный гемоглобин</kwd><kwd>компенсация сахарного диабета</kwd></kwd-group><kwd-group xml:lang="en"><kwd>continuous subcutaneous insulin infusion (CSII)</kwd><kwd>continuous glucose monitoring (CGM)</kwd><kwd>Type 1 Diabetes Mellitus</kwd><kwd>HbA1c</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено в рамках исполнения государственного задания №123021000040-9</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Miller KM, Hermann J, Foster N, et al. Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care. 2020;43(1):e1-e2. https://doi.org/10.2337/dc19-1214</mixed-citation><mixed-citation xml:lang="en">Miller KM, Hermann J, Foster N, et al. Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries. Diabetes Care. 2020;43(1):e1-e2. https://doi.org/10.2337/dc19-1214</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66-72. https://doi.org/10.1089/dia.2018.0384</mixed-citation><mixed-citation xml:lang="en">Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66-72. https://doi.org/10.1089/dia.2018.0384</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Викулова О.К., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010-2022 гг. // Сахарный диабет. — 2023. — Т. 26. — №2. — С. 104–123. https://doi.org/10.14341/DM13035</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104-123. (In Russ.) https://doi.org/10.14341/DM13035</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Beck RW, Tamborlane W V., Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D Exchange Clinic Registry. J Clin Endocrinol Metab. 2012;97(12):4383-4389. https://doi.org/10.1210/jc.2012-1561</mixed-citation><mixed-citation xml:lang="en">Beck RW, Tamborlane W V., Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D Exchange Clinic Registry. J Clin Endocrinol Metab. 2012;97(12):4383-4389. https://doi.org/10.1210/jc.2012-1561</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Blackman SM, Raghinaru D, Adi S, et al. Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes. 2014;15(8):564-572. https://doi.org/10.1111/pedi.12121</mixed-citation><mixed-citation xml:lang="en">Blackman SM, Raghinaru D, Adi S, et al. Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes. 2014;15(8):564-572. https://doi.org/10.1111/pedi.12121</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261-272. https://doi.org/10.1038/s41592-019-0686-2</mixed-citation><mixed-citation xml:lang="en">Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261-272. https://doi.org/10.1038/s41592-019-0686-2</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shan G, Lou X, Wu SS. Continuity Corrected Wilson Interval for the Difference of Two Independent Proportions. J Stat Theory Appl. 2023;22(1-2):38-53. https://doi.org/10.1007/s44199-023-00054-8</mixed-citation><mixed-citation xml:lang="en">Shan G, Lou X, Wu SS. Continuity Corrected Wilson Interval for the Difference of Two Independent Proportions. J Stat Theory Appl. 2023;22(1-2):38-53. https://doi.org/10.1007/s44199-023-00054-8</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Петряйкина Е.Е., Лаптев Д.Н., Воронцова И.Г., и др. Сахарный диабет 1 типа у детей и подростков г. Москвы. Данные Московского сегмента Федерального регистра больных сахарным диабетом 2015–2020 гг. // Проблемы эндокринологии. — 2021. — Т. 67. — №6. — С. 113–123. https://doi.org/10.14341/probl12795</mixed-citation><mixed-citation xml:lang="en">Petryaykina EE, Laptev DN, Vorontsova IG, et al. Diabetes mellitus type 1 in children and adolescents in Moscow. Data from the Moscow Segment of the Federal Register of Diabetic Patients 2015–2020. Problems of Endocrinology. 2021;67(6):113-123. (In Russ.) https://doi.org/10.14341/probl12795</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Петеркова В.А., и др. Сахарный диабет у детей и подростков по данным Федерального регистра Российской Федерации: динамика основных эпидемиологических характеристик за 2013–2016гг // Сахарный диабет. — 2017. — Т. 20. — №6. — С. 392-402. https://doi.org/10.14341/DM9460</mixed-citation><mixed-citation xml:lang="en">Dedov II, Shestakova MV, Peterkova VA, et al. Diabetes mellitus in children and adolescents according to the Federal diabetes registry in the Russian Federation: dynamics of major epidemiological characteristics for 2013–2016. Diabetes mellitus. 2017;20(6):392-402. (In Russ.) https://doi.org/10.14341/DM9460</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD005103. https://doi.org/10.1002/14651858.CD005103.pub2</mixed-citation><mixed-citation xml:lang="en">Misso ML, Egberts KJ, Page M, O’Connor D, Shaw J. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD005103. https://doi.org/10.1002/14651858.CD005103.pub2</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Емельянов А.О., Кураева Т.Л., Лаптев Д.Н., Петеркова В.А. Проспективное наблюдение эффективности и безопасности помповой инсулинотерапии у детей и подростков // Сахарный диабет. — 2010. — Т.48. — №3. — С. 143–146 https://doi.org/10.14341/2072-0351-5503</mixed-citation><mixed-citation xml:lang="en">Emel’yanov AO, Kuraeva TL, Laptev DN, Peterkova VA. Prospective study of efficacy and safety of insulin pump therapy in children and adolescents. Diabetes mellitus. 2010;13(3):143-146. (In Russ.) https://doi.org/10.14341/2072-0351-5503</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Емельянов А.О., Медведева Е.Д., и др. Длительный гликемический контроль и факторы, ассоциированные с ответом на помповую инсулинотерапию у детей // Сахарный диабет. — 2021. — Т.24. — №2. — С. 122–132 https://doi.org/10.14341/DM12530</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Emelyanov AO, Medvedeva ED, et al. Long-term glycemic control and factors, associated with response to pump insulin therapy in children. Diabetes mellitus. 2021;24(2):122-132. (In Russ.) https://doi.org/10.14341/DM12530</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Безлепкина О.Б., Демина Е.С., и др. Результаты клинической апробации системы FreeStyle Libre у детей с сахарным диабетом 1 типа: улучшение гликемического контроля в сочетании со снижением риска тяжелой гипогликемии и диабетического кетоацидоза // Проблемы эндокринологии. — 2022. — Т. 68. — №3. — С. 86–92 https://doi.org/10.14341/probl12877</mixed-citation><mixed-citation xml:lang="en">Laptev DN, Bezlepkina OB, Demina ES, et al. Evaluation of FreeStyle Libre in pediatric t1dm: improved glycemic control, reduction in diabetic ketoacidosis and severe hypoglycemia. Problems of Endocrinology. 2022;68(3):86-92. (In Russ.) https://doi.org/10.14341/probl12877</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri O. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes. 2018;19(7):1294-1301. https://doi.org/10.1111/pedi.12735</mixed-citation><mixed-citation xml:lang="en">Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri O. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes. 2018;19(7):1294-1301. https://doi.org/10.1111/pedi.12735</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Boucher SE, Gray AR, de Bock M, et al. Effect of 6 months’ flash glucose monitoring in adolescents and young adults with type 1 diabetes and suboptimal glycaemic control: managing diabetes in a ‘flash’ randomised controlled trial protocol. BMC Endocr Disord. 2019;19(1):50. https://doi.org/10.1186/s12902-019-0378-z</mixed-citation><mixed-citation xml:lang="en">Boucher SE, Gray AR, de Bock M, et al. Effect of 6 months’ flash glucose monitoring in adolescents and young adults with type 1 diabetes and suboptimal glycaemic control: managing diabetes in a ‘flash’ randomised controlled trial protocol. BMC Endocr Disord. 2019;19(1):50. https://doi.org/10.1186/s12902-019-0378-z</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. Diabetes Care. 2011;34(11):2403-2405. https://doi.org/10.2337/dc11-1248</mixed-citation><mixed-citation xml:lang="en">Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study. Diabetes Care. 2011;34(11):2403-2405. https://doi.org/10.2337/dc11-1248</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Abraham MB, Nicholas JA, Smith GJ, et al. Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes. Diabetes Care. 2018;41(2):303-310. https://doi.org/10.2337/dc17-1604</mixed-citation><mixed-citation xml:lang="en">Abraham MB, Nicholas JA, Smith GJ, et al. Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes. Diabetes Care. 2018;41(2):303-310. https://doi.org/10.2337/dc17-1604</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Passanisi S, Lombardo F, Mameli C, et al. Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780GTM in Children, Adolescents and Young Adults: A Systematic Review. Diabetes Ther. 2024;15(2):343-365. https://doi.org/10.1007/s13300-023-01501-6</mixed-citation><mixed-citation xml:lang="en">Passanisi S, Lombardo F, Mameli C, et al. Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780GTM in Children, Adolescents and Young Adults: A Systematic Review. Diabetes Ther. 2024;15(2):343-365. https://doi.org/10.1007/s13300-023-01501-6</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23(8):1270-1276. https://doi.org/10.1111/pedi.13455</mixed-citation><mixed-citation xml:lang="en">de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23(8):1270-1276. https://doi.org/10.1111/pedi.13455</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
